Borer Denton & Associates Inc. Has $13.63 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Borer Denton & Associates Inc. decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 114,472 shares of the company’s stock after selling 750 shares during the quarter. Novo Nordisk A/S makes up approximately 4.6% of Borer Denton & Associates Inc.’s holdings, making the stock its 6th largest holding. Borer Denton & Associates Inc.’s holdings in Novo Nordisk A/S were worth $13,630,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. 1620 Investment Advisors Inc. acquired a new position in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Halpern Financial Inc. boosted its position in shares of Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. Finally, Abound Wealth Management grew its stake in shares of Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent analyst reports. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $105.06 on Friday. The firm’s 50 day moving average price is $115.48 and its two-hundred day moving average price is $128.80. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The firm has a market cap of $471.46 billion, a P/E ratio of 34.00, a PEG ratio of 1.32 and a beta of 0.42.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.